Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood.

The presence of estrogen receptor (ER) is a well-known predictor of clinical outcome in human breast cancer. We examined the ER gene in 26 primary breast cancers (14 ER-positive, 12 ER-negative) to determine if alterations of the gene are associated with the ER-negative status. In tumor biopsies and peripheral blood DNA obtained from the same patients we analyzed the ER exon structure using polymerase chain reaction amplification, restriction endonuclease digestion, and agarose gel electrophoresis. All blood and tumor samples, regardless of ER status, showed a complete set of eight exons of normal sizes, ruling out deletions or rearrangements of the ER gene in excess of +/- 20 nucleotides. Previous reports indicate that the two-allele ER PvuII polymorphism could be associated with ER expression in breast cancer (Hill et al., Cancer Res., 49: 145-148, 1989) as well as with patient age at time of tumor diagnosis (Parl et al., Breast Cancer Res. Treat., 14: 57-64, 1989). We localized the PvuII polymorphism in intron 1, 0.4 kilobase upstream of exon 2. Sequence analysis showed the polymorphism to result from a point mutation (T----C) at the fifth position of the restriction site (CATCTG). We determined the PvuII restriction fragment-length polymorphism genotype in 257 primary breast cancers and 140 peripheral blood DNA samples obtained from women without breast cancer. The results indicate that the PvuII polymorphism is not associated with ER content or patient age at tumor diagnosis.

[1]  K. Struhl,et al.  Current Protocols in Molecular Biology (New York: Greene Publishing Associates and Wiley-Interscience). Host-Range Shuttle System for Gene Insertion into the Chromosomes of Gram-negative Bacteria. , 1988 .

[2]  G. Auer,et al.  Predictive value of nuclear DNA content in breast cancer in relation to clinical and morphologic factors. A retrospective study of 227 consecutive cases , 1988, Cancer.

[3]  M. Gordon,et al.  Computer modeling of estradiol interactions with the estrogen receptor. , 1986, Journal of steroid biochemistry.

[4]  W. McGuire.  Estrogen receptors in human breast cancer. , 1973, The Journal of clinical investigation.

[5]  A. Linstedt,et al.  Analysis of monomeric-dimeric states of the estrogen receptor with monoclonal antiestrophilins. , 1986, Journal of steroid biochemistry.

[6]  Gerhart U. Ryffel,et al.  An estrogen-responsive element derived from the 5′ flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells , 1986, Cell.

[7]  F. Parl,et al.  Discrepancies of the biochemical and immunohistochemical estrogen receptor assays in breast cancer. , 1988, Human pathology.

[8]  J. Gosden,et al.  Localization of the human oestrogen receptor gene to chromosome 6q24----q27 by in situ hybridization. , 1986, Cytogenetics and cell genetics.

[9]  R. Evans,et al.  Identification of a new class of steroid hormone receptors , 1988, Nature.

[10]  N. Webster,et al.  The human estrogen receptor has two independent nonacidic transcriptional activation functions , 1989, Cell.

[11]  B. O’Malley,et al.  An ochre mutation in the vitamin D receptor gene causes hereditary 1,25-dihydroxyvitamin D3-resistant rickets in three families. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Y. Nomura,et al.  [Hormone-dependency of human breast cancer in in vitro clonogenic assay]. , 1987, Gan no rinsho. Japan journal of cancer clinics.

[13]  G. Chalepakis,et al.  Gene regulation by steroid hormones. , 1989, Cell.

[14]  Rupert G. Miller.  Simultaneous Statistical Inference , 1966 .

[15]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[16]  K. Yamamoto,et al.  Glucocorticoid receptor mutants that define a small region sufficient for enhancer activation. , 1987, Science.

[17]  E. Jensen.  Hormone dependency of breast cancer , 1981, Cancer.

[18]  N. E. Breslow.  Statistical Methods in Cancer Research , 1986 .

[19]  W. McGuire,et al.  DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens , 1988, Cancer.

[20]  W. McGuire,et al.  The value of estrogen and progesterone receptors in the treatment of breast cancer , 1980, Cancer.

[21]  M. Hultén,et al.  Cytogenetic analysis in human breast carcinoma. I. Nine cases in the diploid range investigated using direct preparations. , 1984, Cancer genetics and cytogenetics.

[22]  P. Chambon,et al.  Genomic organization of the human oestrogen receptor gene. , 1988, The EMBO journal.

[23]  A. Feinberg,et al.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. , 1983, Analytical biochemistry.

[24]  M. Lippman,et al.  Quantitative estrogen receptor analyses: The response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease‐free interval , 1980, Cancer.

[25]  M. Hultén,et al.  Cytogenetic analysis in human breast carcinoma. II. Seven cases in the triploid/tetraploid range investigated using direct preparations. , 1987, Cancer genetics and cytogenetics.

[26]  W. Jonat,et al.  The problem of nonresponding estrogen receptor‐positive patients with advanced breast cancer , 1980, Cancer.

[27]  F. S. French,et al.  Deletion of the steroid-binding domain of the human androgen receptor gene in one family with complete androgen insensitivity syndrome: evidence for further genetic heterogeneity in this syndrome. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Dabska,et al.  Estrogen Receptor in Human Breast Cancer in Relation to Tumor Morphology and Endocrine Therapy 1 , 1978, Tumori.

[29]  B. O’Malley,et al.  Mechanism of estrogen receptor-dependent transcription in a cell-free system , 1990, Molecular and cellular biology.

[30]  N. Breslow,et al.  Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. , 1981 .

[31]  W. McGuire,et al.  Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. , 1989, Cancer research.

[32]  P. Chambon,et al.  Cloning of the chicken progesterone receptor. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Shine,et al.  Sequence and expression of human estrogen receptor complementary DNA. , 1986, Science.

[34]  J. Fleiss.  Statistical methods for rates and proportions , 1974 .

[35]  James H. Torrie,et al.  Principles and procedures of statistics: a biometrical approach (2nd ed) , 1980 .

[36]  P. Chambon,et al.  The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer , 1988, Cell.

[37]  P. Argos,et al.  Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A , 1986, Nature.

[38]  D. Housman,et al.  Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. , 1987, Science.

[39]  J. Harmon,et al.  Glucocorticoid receptor expression in receptorless mutants isolated from the human leukemic cell line CEM-C7. , 1989, Molecular endocrinology.

[40]  A. Manni,et al.  Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy , 1980, Cancer.

[41]  E. Meese,et al.  nti glucocorticoid receptor transcripts lack sequences encoding the amino-terminal transcriptional modulatory domain , 1990, Molecular and cellular biology.

[42]  A. Mérillat,et al.  Identification of estrogen-responsive DNA sequences by transient expression experiments in a human breast cancer cell line. , 1986, Nucleic acids research.

[43]  S. Fawell,et al.  Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor , 1990, Cell.

[44]  P. Chambon,et al.  Functional domains of the human estrogen receptor , 1987, Cell.

[45]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[46]  D. Seckinger,et al.  Prognostic indicators including DNA histogram type, receptor content, and staging related to human breast cancer patient survival. , 1984, Cancer research.